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Abstract
Background: A link between progressive dental malocclusion, the use of a continuous positive airway pressure
mask and GH-secreting pituitary macroadenoma (acromegaly) has not been previously reported. The present
clinicopathological analysis stresses that tooth malposition should not be seen exclusively as a local process.
Case presentation: A 62-year-old caucasian man with no relevant medical history reported difficulty chewing food
and perceived voice alteration during his annual periodontal check-up. He also referred stiffness of the tongue, face,
and submandibular area. The patient had been diagnosed with obstructive sleep apnea syndrome two years previously,
since when he had worn a continuous positive airway pressure device during sleep. Exploration of the occlusion revealed
significant changes: an atypical left lateral and anterior open bite with major buccoversion of teeth 33, 34, 35, 36.
Inspection of the soft tissue revealed only macroglossia, although external palpation indicated a subcutaneous stiffness of
the submandibular area. General analytical tests, including hormone profiles, and magnetic resonance imaging confirmed
the diagnosis of acromegaly induced by a pituitary adenoma. Intrasellar tumor resection via transsphenoidal approach
was performed. After surgery, the patient already noted a marked improvement of all symptoms associated with the
acromegaly. Desaturation data also evolved favourably and the pulmonologist advised the patient to abandon the
continuous positive airway pressure treatment.
Conclusion: Progressive dental malocclusion may be associated with a systemic disease and the use of a nasal mask with
premaxillary support may distort the diagnosis of acromegaly.
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Background
In the case described here, a dental malocclusion was
the starting point for the identification of an intracranial
neoplasia which was concealed by the presence of
obstructive sleep apnea syndrome (OSAS) and by the
use of a nasal mask for continuous positive airway
pressure (CPAP) treatment. The clinicopathological ana-
lysis of this progressive dental malocclusion in a CPAP
mask user shows that tooth malposition should not be
seen exclusively as a local process.
Case presentation
A 62-year-old caucasian man with no relevant medical
history reported difficulty chewing food and perceived
voice alteration during his annual periodontal check-up.
He also referred stiffness of the tongue, face, and sub-
mandibular area. The patient had been diagnosed with
severe OSAS two years previously, since when he had
worn a CPAP device during sleep. Polysomnography
(PSG) showed an Apnea-Hypopnea Index (AHI) of 54.6.
The lowest value of SaO2 (%) desaturation was 69, and it
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was below 90 for 43.5% of the total time asleep. At the
first patient wore a mask that covered the mouth and nose
with a flow of 9 cm H2O (Fig. 1a). However, after a control
polysomnography at 14 months he was instructed to in-
crease the flow pressure to 11 cm H2O, and for reasons of
comfort he opted for an exclusively nasal mask. During
the check-up with his periodontist, the mask was adjusted
to assess the force exerted on the oral, dental and facial
structures (Fig. 1b). The patient associated the changes in
mastication with the pressure exerted by the last nasal
mask on the area of the premaxilla and the upper incisors
over recent months.
Exploration of the occlusion with the aid of an ortho-
dontist revealed significant changes. An atypical left lateral
and anterior open bite was observed, with major buccov-
ersion of teeth 33, 34, 35, 36, along with a slight diastema
of the lower incisors, without tooth mobility (Fig. 2a,b,c).
A soft tissue inspection revealed only macroglossia,
with the tongue resting on the occlusal surfaces of
the teeth of the lower arch (Fig. 3a,b). Fortunately,
the availability of a set of study plaster models cre-
ated five years previously allowed us to measure and
accurately quantify the expansion of the jaws by using
a digital caliper (Fig. 4).
External palpation indicated a subcutaneous stiffness
of the submandibular area. Orthopantomography was
normal, although the lateral X-ray of the skull and
cephalometric analysis showed abnormally high angles
of inclination of the lower incisor with regard to the axis
of the mandibular body and tooth plane (Fig. 5).
Diagnosis and management
On the same day as the visit, orthopantomography
and lateral cephalometry were performed, revealing a
reduction of the upper airway with thickening of the
soft tissue. General analytical tests were performed imme-
diately, including hormone profiles. The extremely high
values of growth hormone (11.8 ng/mL – normal range
0.02-1.23) and insulin-like growth factor 1 (780.2 ng/mL –
normal range 15-246) confirmed the diagnosis of acro-
megaly and ruled out the rest of entities included in the
differential diagnosis, such as pathological tooth migra-
tion, jaw expansive process, amyloidosis, hypothyroidism,
rhinolalia and systemic voice disorders.
The patient was referred to an endocrinologist who re-
quested a magnetic resonance imaging (MRI) of the pi-
tuitary gland with intravenous contrast. A significant
growth of the left side of this gland (11.5x9.5 mm) was
identified and the image was compatible with a pituitary
macroadenoma (Fig. 6).
To complete the preoperative study, neuronavigation
computed tomography with intravenous contrast was
performed, which confirmed the left intrasellar tumor.
Finally, the patient underwent tumor resection via a
transsphenoidal approach, conducted by a neurosur-
geon. Postoperative evolution was satisfactory and
histopathological analysis confirmed the diagnosis of
densely granulated somatotroph pituitary macroade-
noma (Fig. 7).
A few days after surgery, the patient already noted a
marked improvement of all symptoms associated with the
acromegaly and decided not to resume CPAP treatment.
In addition desaturation data also evolved favorably during
follow-up: the lowest SaO2 (%) value was 87.60 and it was
below 88% for only 0.02% of the total time asleep. Conse-
quently, the pulmonologist advised the patient to abandon
the CPAP. Within only two months, the analytical values
showed a clear trend towards normalization: growth
hormone (GH) 0.305 ng/mL and insulin-like growth
factor 1 (IGF-1) 302.6 ng/mL.
Fig. 1 a) Oronasal (facial) mask. b) Nasal mask with support on the premaxillary area
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Discussion
Pituitary adenomas are benign neoplasms arising from
cells of the anterior pituitary gland and constitute 10-
15% of intracranial tumors. From the clinicopathological
point of view, they are divided into as somatotroph
adenomas, which produce growth hormone; lactotroph
adenomas, which produce prolactin; thyrotroph aden-
omas, which produce thyroid-stimulating hormone
(TSH); corticotroph adenomas, which produce adreno-
corticotropic hormone ACTH); and gonadotroph aden-
omas, which produce gonadotropin [1]. It is extremely
unusual for the dentist to suspect a somatotroph pituit-
ary adenoma during a periodontal maintenance visit.
Patients with acromegaly are usually diagnosed late
(>3 years) and at very advanced stages of the disease. In
our case, the time to diagnosis was approximately two
years; when OSAS was diagnosed, acromegaly should
have been suspected. About 40% of cases of acromegaly
are diagnosed by internists, and they may also be diag-
nosed by specialists in sleep obstructive disorders or
ophthalmologists [2]. Acromegaly usually causes cranio-
facial abnormalities and indeed almost all cases present
significant changes in oral and dental structures. The fa-
cial changes typically associated with acromegaly include
an increasingly prominent forehead, growth of the nose
and ears, thickening of the lips and the development of
marked nasolabial folds. Patients also present mandibu-
lar prognathism, which may cause malocclusion and dia-
stema [3, 4]. Macroglossia is common in these patients
and contributes to the occurrence of OSAS. The voice is
characteristically sonorous, associated with laryngeal
hypertrophy and enlargement of the sinuses [5]. In view
of the major impact of changes in the orofacial area and
the dental occlusion, Herrmann et al concluded patients
with acromegaly require good oral and maxillofacial
examination in strict co-operation between endocrinolo-
gists, dentists and oral surgeons [6]. Kashyap et al.
suggest that acromegaly should be considered in patients
who develop malocclusion after adolescence [7].
The persistence of high levels of GH and IGF-1 in
patients with acromegaly raises the mortality rate to 30%
[2]. The factors that contribute to the increased mortal-
ity in these patients include cardiovascular disorders
(60%), respiratory disorders with sleep apnea (25%),
neoplasms and hyperglycemia or overt diabetes [8].
The treatment of GH-secreting pituitary adenoma
aims to normalize the values of the altered biochemical
markers, to eliminate or control the associated tumor
without damaging the pituitary function and to eliminate
the signs and symptoms [9]. Currently, treatment com-
prises a combination of medical and surgical therapy.
Three types of drugs are available: somatostatin analogs
(SSA) such as lanreotide, dopamine agonists such as
cabergoline and, above all, GH receptor antagonists such
as pegvisomant [10].
Although most clinical guidelines advocate surgery as
first-line treatment [11], Fougner et al’s meta-analysis
observed a trend towards the use of medical therapy
Fig. 2 Clinical images. a) Right occlusion, showing a class III occlusion with loss of occlusal contacts due to the expansion caused by the
macroglossia. b) Maximum intercuspidation (front view). Note the loss of contacts with a tendency towards open bite and the diastema in the
anterior lower sector. c) Left occlusion, showing the posterior open bite associated with the growth and pressure of the tongue
Fig. 3 a) Clinical image of macroglossia. The tongue invades occlusal surfaces of the lower arch. b) Note the buccal version of teeth 35 and 36
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prior to surgery [12]. One of the consensus groups on
acromegaly recently recommended drug treatment com-
bining a long-acting SSA and pegvisomant in patients in
whom GH and IGF-1 levels did not decrease with som-
atostatin agonists alone (around 50% of cases) [13].
The cure rates achieved using transsphenoidal surgery
differ significantly depending on the size of the tumor
and the experience of the neurosurgeon. Success rates of
around 78% in surgery for microadenomas (<1 cm) and
around 50% in macroadenomas (> 1 cm) have been
reported [13]. A recent study using data from the UK
National Acromegaly Registry reported success rates be-
tween 20 to 40% with transsphenoidal surgery [14].
The association between acromegaly and OSAS has
been reported previously [15, 16]. Seventy-three percent
of patients with acromegaly present enlarged goiters and
a high prevalence of type II diabetes [15, 17], but the size
of the thyroid and the glucose metabolism are not suffi-
cient to explain the association between acromegaly and
OSAS. An excess of GH and IGF-1 lead to anatomical
changes in craniofacial bones, soft tissues, and respira-
tory mucosa, so these patients often develop OSAS (as
Fig. 4 Measurement of the growth of the jaws in cross-sectional direction using a digital caliper in previous and current plaster models. Note the
increases in the upper and lower distances between the teeth (2 mm and 7 mm respectively)
Fig. 5 Comparison of lateral cephalometric x-ray previous to tumor resection and 12 months later. Note the normalization of the morphology of
the sella turcica and the improvement in the inclination of the maxillary incisors
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many as 80-90% in some series) day time narcolepsy,
and cognitive impairment severe enough the quality of
life. Acromegaly is also associated with “central apnea”
which streams from alterations in the non-behavioral
system controlling ventilation caused by the direct ef-
fects of GH/IGF-1 levels on the respiratory center [15].
Treatment with CPAP is effective in controlling sleep
disorders in patients with acromegaly, although the re-
sults for the normalization of GH/IGF-1 and the im-
provement of OSAS are controversial [18–20]. In our
case, the patient presented improvements in clinical
symptoms and oxygen saturation levels after the inter-
vention, coinciding with declining levels of GH/IGF-1.
Some authors have claimed that obesity is related to
OSAS [21], but our patient had a body mass index (BMI)
of 23. To rule out subclinical disease in patients suffering
from sleep apnea, especially in those who are not over-
weight, an analytical hormonal profile is required.
Our study raises important questions about the appli-
cation of different types of oronasal or nasal face masks
for CPAP treatment and the presence of progressive
dental malocclusion in these patients. To date, few stud-
ies have discussed the link between these two variables.
The limited evidence available shows an association be-
tween prolonged use of the nasal mask and progressive
occlusal and lateral variations in lateral and anterior sec-
tions, and suggests that the mask may also be the cause
of open bite [22].
Pneumologists and sleep disorder specialists should be
alert to the possibility of acromegaly in OSAS patients.
Dental, oral and maxillofacial specialists should also be
able to recognize specific local signs (not only tongue
volume) that are suggestive of acromegaly. Patients who
are candidates for treatment with CPAP should undergo
a thorough anamnesis, especially if they have macroglos-
sia associated with stiffness of facial tissues. It is import-
ant to ask patients about the growth of hands, feet, nose,
and the sensation of distended and globular abdomen
due to generalized visceromegaly. Patients with acro-
megaly may also experience growth in both prostate and
colon leading to slow intestinal transit, constipation and
difficulty urinating. Some studies show a higher preva-
lence of intestinal polyps and colon cancer [23].
In acromegaly, the trend towards mandibular growth
involves protrusion and widening which, together with
the macroglossia, causes the malocclusion and diastema
observed. In addition, it is usually accompanied by a
hypertrophy of the laryngeal tissues that may cause alter-
ations in the voice [11]. All these changes in the mouth,
teeth, face and voice were identified in our patient.
Fig. 6 MRI study of the pituitary gland with IV contrast medium.
Tomography in a) sagittal and b) coronal planes. Left intrasellar
lesion measuring 11.5 × 9.5 mm touching the cavernous sinus wall.
Note the normal glandular tissue on the right, the deformity of the
floor of the sella, and the central position of the pituitary stalk
Fig. 7 Microscopic appearance. a) Immunohistochemical study of GH indicating granular and diffuse staining patterns in the cytoplasm of tumor
cells. b) Altered architecture with cells presenting moderate pleomorphism and abundant cytoplasm (H&E, original magnification 20×)
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Although many patients with acromegaly are successfully
operated on or treated and show improvement of their
AHI, normalization is infrequent because many anatomical
aspects are not reversed. However, the favorable postsurgi-
cal evolution of this patient suggests that the OSAS could
be attributed to macroglossia, subcutaneous stiffness of the
submandibular area, and hypertrophy of the laryngeal
tissues secondary to acromegaly. Significantly, after the re-
moval of the pituitary adenoma and the ensuing reduction
in the volume of orofacial soft tissue next to the airway,
even though a second polysomnography was not per-
formed after surgery the OSAS improved markedly and
the desaturation data evolved favorably, with the result that
the patient was able to abandon CPAP treatment.
Twelve months after tumor resection, the lateral ceph-
alometric x-ray revealed a normalization of the morph-
ology of the sella turcica. It also showed an improvement
in the inclination of the maxillary incisors (Fig. 5). These
changes can probably be attributed to the reduction of the
volume of the tongue and consequently to the fall in pres-
sure exerted on the incisors. At present the patient reports
far less difficulty speaking, chewing and swallowing.
Conclusions
In summary, progressive dental malocclusion may be
associated with a systemic disease, and the use of a nasal
mask with premaxillary support may distort the diagno-
sis of acromegaly. Only by raising awareness of acromeg-
aly among specialists in different areas can the currently
unacceptable delay in its diagnosis be reduced. A proto-
col that includes an oral examination and a hormone
study should be applied both in patients suffering from
sleep apnea and in patients with atypical progressive
malocclusion associated with macroglossia.
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